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and IFN-alpha alone (US$29,000). The ICER’s per PFM and OS resulted in US$3767.0 
and US$5668.8 (sunitinib vs. IFN-alpha alone). Results were robust to second-order
Monte Carlo sensitivity analysis (10,000 iterations). Acceptability curves showed that 
sunitinib would be a cost-saving strategy against sorafenib and bevacizumabIFN-
alpha with a probability over 70%(p  0.05). CONCLUSIONS: Results show that
sunitinib as ﬁ rst-line treatment is a cost-effective alternative among the new agents for
patients with mRCC.
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OBJECTIVES: There exists a lack of studies for cost-effectiveness analysis on treating
hepatocellular carcinoma (HCC). This study aimed at estimating life expectancy (LE), 
lifetime costs, and incremental cost-effective ratios (ICER) for ﬁ ve different treatments 
of HCC, using a semiparametric method. METHODS: A retrospective cohort study
was performed of a 1,000,000-person random sample obtained from Taiwan’s
National Health Insurance (NHI) reimbursement database. A total of 1932 newly-
diagnosed patients with HCC were indentiﬁ ed and veriﬁ ed with independent ﬁ le of 
catastrophic illnesses. These patients were followed from 1997 to 2003 with longitu-
dinal claim data, including all orders and costs of inpatient services, outpatient ser-
vices, and prescriptions dispensed at pharmacies. They were further stratiﬁ ed to ﬁ ve 
subgroups with different treatments, comprised of surgery, percutaneous ethanol injec-
tion (PEI), transarterial chemoembolization (TACE), chemotherapy and radiotherapy, 
and supportive care. The lifetime survival (up to 50 years) was estimated using the 
Monte Carlo method as well as borrowing information from the general population.
The lifetime costs were estimated by integrating the lifetime survival function and cost
function with some assumptions after the follow-up limit. The ICER was also calcu-
lated as the net cost of four different treatments study groups divided by the increased
number of life years, compared with the supportive care. RESULTS: The LE on overall 
HCC patient was 35.73 months. The surgery group had the longest LE (85.73 
months), and the supportive care group had the shortest LE (15.97 months). The 
surgery was the most cost-effectiveness treatment, which the ICER was 2358 USD per
life year (LY) after lifetime follow-up. The PEI (7124 USD/LY) was more cost-effective 
than TACE (7767 USD/LY). CONCLUSIONS: The study applied semiparametric 
method to project lifetime survival and lifetime costs, using the real cost data through 
national longitudinal reimbursement database, which might be an alternative method 
with retrospective approach on cost-effectiveness analysis.
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OBJECTIVES: To estimate the incremental cost-effectiveness of bortezomib (BTZ)
compared with lenalidomide plus dexamethasone (LENDEX) and dexamethasone 
(DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden.
METHODS: We constructed a model, using Microsoft Ofﬁ ce Excel 2003 and VBA
6.3 software, to compare the BTZ, LENDEX and DEX regimens for relapsed/refrac-
tory multiple myeloma. The effects of treatment on time to progression and overall 
survival (OS) were obtained from published reports of the APEX, MM-009 and MM-
010 randomized clinical trials. Costs include drug and administration costs, adverse 
events, treatment of relapses, and end-of-life costs. Utility estimates are derived from
the literature. The analytic framework is based on ‘partitioned survival analysis’ that
allows survival data to be decomposed into three states: 1) alive before disease progres-
sion; 2) alive after progression, and; 3) dead. By computing the amount of time a 
patient is projected to spend in each state, the model estimates mean OS, quality-
adjusted life-years (QALYs), costs and cost per QALY over a 30-year time horizon, 
and performs both 1-way and probabilistic sensitivity analyses. RESULTS: BTZ mean
OS is 38.6 months compared to 24.5 and 37.8 months for DEX and LENDEX 
respectively. Mean lifetime direct medical costs per patient are approximately SEK 
562,000, 1,064,000 and 1,641,000 for DEX, BTZ and LENDEX respectively. Mean
incremental cost per QALY of BTZ compared to DEX is SEK 618,000; 95th percentile 
(424,000, 877,000) and is dominant with respect to LENDEX. The two most inﬂ u-
ential variables in our model are (1) utility prior to relapse, and (2) cost of BTZ che-
motherapy. CONCLUSIONS: BTZ and LENDEX are projected to prolong survival
relative to DEX. From a Swedish perspective, BTZ is cost-effective compared to both
DEX and LENDEX, and the incremental cost per QALY is below the threshold set 
by the World Health Organization.
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OBJECTIVES: In Canada, colorectal cancer (CRC) screening is recommended for
average-risk individuals age 50–75. A variety of options are available for screening
those at average risk for CRC, including stool-based tests (such as fecal occult blood 
test (FOBT), fecal immunochemical tests (FITs), and fecal DNA), radiological studies 
(such as Computed tomographic colonography (CTC)) and colonoscopy. Each modal-
ity differs in terms of test performance characteristics, invasiveness, safety and costs.
The objective of this study is to perform an economic evaluation of CRC screening 
considering all of the available CRC screening modalities using a Canadian perspective.
METHODS: Using decision analysis, to compare CRC screening by FIT, fecal DNA, 
CTC and the most widely utilized CRC screening strategies (FOBT and colonoscopy) 
with no screening in average risk Canadians aged 50 to 74. Outcomes included the
number of colonoscopies required, cancers, death from cancer, cost and cost per
quality-adjusted life year (QALY) gained. Model inputs were obtained from the litera-
ture and a meta-analysis of adenoma prevalence. A lifetime horizon and 5% discount-
ing was used in the analysis. All costs are reported in Canadian dollars and were inﬂ ated 
to 2007. RESULTS: In a hypothetical 100,000 patient cohort, we determined that all 
strategies (FOBT, fecal DNA, CTC, and colonoscopy) were associated with worse clini-
cal outcomes and higher costs than FIT, and thus were “dominated” by FIT. Compared
with no screening, FIT was associated with a cost per QALY gained of $3410. This
result was robust to plausible changes in known parameters. CONCLUSIONS: CRC 
screening appears cost-effective by conventional standards in comparison to the most 
common management of average risk Canadians (no screening). Although some uncer-
tainty exists as to the optimal screening strategy, FIT appears to be the optimal strategy
if the primary goal is to minimize the cost at which QALYs are purchased.
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OBJECTIVES: The US Oncology Adjuvant Trial 9735 has demonstrated an overall
survival (OS) beneﬁ t over 7 years for docetaxel plus cyclophosphamide (TC) compared 
with doxorubicin plus cyclophosphamide (AC) as adjuvant treatment for women with 
operable stage I-III invasive breast cancer. However, the cost of the TC regimen is much
higher than AC. The objective of this analysis was to evaluate the cost-effectiveness
of TC vs. AC from the perspective of the US payers. METHODS: A lifetime decision 
model with 3% discount rate was developed to estimate incremental cost (IC) per life-
year (LY) gained and IC per quality-adjusted life-year (QALY) gained. The OS beneﬁ t
of TC compared with AC over the 7-year trial period was extrapolated to lifetime using 
life expectancy of age-matched women in the general US population. Chemotherapy 
drug costs were calculated using standard dosage schedule combined with the US 
average sale price  6%. Cost associated with chemotherapy administration, and treat-
ments per episode of recurrence and adverse events were estimated from retrospective 
analyses using US claims databases. Parameter uncertainties were assessed using one-
way sensitivity analyses. RESULTS: The projected per person LYs and QALYs gained 
for TC compared with AC were 0.850 and 0.674, respectively. The estimated IC per 
person was $5325. The IC per LY and QALY gained per person were $6261 and $7905, 
respectively. The results were robust across a wide range of sensitivity analyses; in 
particular, the IC per LY and QALY gained remained under $50,000 when the duration
of the analysis was limited to 7 years. CONCLUSIONS: This analysis shows that use 
of the TC regimen compared to the standard AC regimen in patients with operable 
stage I-III breast cancer is a cost-effective treatment strategy.
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OBJECTIVES: To estimate the long-term health economic outcomes for patients 
treated with either bevacizumab added to chemotherapy or chemotherapy alone, as 
adjuvant treatment for patients with triple-negative breast cancer (TNBC). METHODS:
We used a three-state Markov Model (Disease-Free Survival (DFS), Progressed, Death)
to estimate the impact of adding one year of adjuvant treatment with bevacizumab to
an established chemotherapy regimen. The probability of disease recurrence was 
derived from a prospective clinical database analysis of 255 patients with early TNBC.
The treatment effect of bevacizumab was incorporated by applying a relative risk
reduction to the underlying risk of disease recurrence, using the expected hazard ratio 
(0.75), from the statistical power calculations of the on-going phase III BEATRICE 
study; a trial recruiting solely patients with early TNBC. Total direct medical costs
and quality-adjusted life expectancy (QALYs) were projected over patient lifetimes
from the perspective of the UK NHS. Clinical and economic outcomes were discounted
at 3.5% per annum. Probabilistic and univariate sensitivity analyses were performed.
RESULTS: Mean discounted quality-adjusted life expectancy was projected to increase 
by 0.83 QALYs following the addition of bevacizumab to chemotherapy versus che-
motherapy alone (11.35 vs 10.53 QALYs). Over patient lifetimes, discounted total
direct costs were estimated to be higher with bevacizumab, primarily attributed to 
higher pharmacy costs and the increased time spent in DFS. These results corresponded
to an incremental cost-effectiveness ratio of a43,804/QALY gained. Sensitivity analysis 
indicated results were most sensitive to the duration of the treatment effect of bevaci-
zumab and patients’ baseline characteristics (height and weight). CONCLUSIONS:
